Quintiles launches Allume support services

Friday, July 13, 2012 03:19 PM

Quintiles has introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume simplifies and organizes the complex and resource-intensive launch planning process, provides unique data-driven insights from market-entry experience across the globe and taps Quintiles’ local market and therapeutic category expertise.

“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, vice president, consulting, at Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets.”

Allume combines consulting, clinical and commercial expertise with with state-of-the-art software, incorporating Quintiles’ biopharma product launch experience into support to complement in-house capabilities. It can be customized to each company and product to help identify key market challenges, fast-track launch rollout and efficiency in resource management.

 

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs